DEM BioPharma
Latest round
- Series A
Last raised
- May 2022
Total raised
- $18M
Investors
- 8
About DEM BioPharma
In 2022, the company was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik. The company runs a platform called CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) can be used to explore new DEM and EM signals via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells.
Who invested in DEM BioPharma
8 investors across 1 round
See all investors in DEM BioPharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 8, 2022
Amount
$18M
Investors
Questions about DEM BioPharma
Who invested in DEM BioPharma?
DEM BioPharma has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has DEM BioPharma raised?
DEM BioPharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did DEM BioPharma last raise money?
DEM BioPharma's most recent round on record is a Series A, in May 2022.
What does DEM BioPharma do?
In 2022, the company was co-founded by the Longwood Fund and distinguished scientists Drs.
Where is DEM BioPharma headquartered?
DEM BioPharma is headquartered in Cambridge, US.
Which VCs invest in companies like DEM BioPharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at DEM BioPharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like DEM BioPharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.